<DOC>
	<DOCNO>NCT01218230</DOCNO>
	<brief_summary>Intravitreal pegaptanib treatment choroidal neovascularisation secondary pathologic myopia</brief_summary>
	<brief_title>Intravitreal Pegaptanib Treatment Choroidal Neovascularisation Secondary Pathologic Myopia</brief_title>
	<detailed_description>This Prospective Interventional , non-comparative study 20 consecutive patient select outpatient service . After take informed consent , patient give intravitreal Pegaptanib 0.3 mg every 6 week 3 procedure injection . Thereafter , patient continue examine every 6 week ( ± 2 week ) may receive additional injection need base presence one re-treatment criterion ( please see ) . Final assessment do 54 week baseline investigation perform .</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>1 . Should willing participate trial . 2 . Age le 55 year . 3 . Best correct visual acuity ( BCVA ) score least 5 letter ( 20/200 ) , assess ETDRS chart . 4 . Myopia ≥ 6 Diopters . 5 . Fluorescein angiographic documentation CNV . 1 . Ocular cause , ocular disorder lead vision loss . 2 . Maculopathy related pathologic myopia . 3 . Pregnancy , lactation . 4 . Not willing provide inform consent . 5 . History previous macular laser include PDT . 6 . Other form therapy include intravitreal injection . 7 . History intraocular surgery past 3 month . 8 . Anticipated cataract surgery next 6 month . 9 . Any active infection inflammation eye . 10 . Cases good quality image possible , either due hazy medium extremely high myopia . 11 . Patients uncontrolled glaucoma , IOP &gt; 21mm Hg 2 medication . 12 . Patients subfoveal scar significant subretinal haemorrhage occupy 50 % lesion size . 13 . Eyes previous retinal detachment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pegaptanib , myopic CNVM , intravitreal anti-VEGF</keyword>
</DOC>